Berkshire Biomedical Corporation is gearing up to close its equity crowdfunding campaign on StartEngine, with a final investor-focused webinar scheduled for Thursday, April 24, at 1:30 PM PST. The webinar will delve into the transformative potential of Berkshire’s COPA™ (Computerized Oral Prescription Administration) technology in addressing critical challenges related to medication safety, adherence, and misuse across various therapeutic categories.
Although COPA’s initial focus is on Medication for Opioid Use Disorder (MOUD), its precision, control, and real-time connectivity hold promise for a wide range of applications. The upcoming session will explore how COPA could revolutionize the treatment of chronic pain, ADHD, epilepsy, Alzheimer’s disease, and post-surgical recovery by enhancing outcomes, reducing risks, and enabling personalized care.
Leading the discussion during the webinar will be John Timberlake, President and CEO of Berkshire Biomedical, alongside Tom King, Senior Advisor to the Company. The speakers will also highlight COPA’s potential value to clinical research organizations and pharmaceutical partners as a digital drug delivery platform for clinical trials and high-risk medications.
Attendees can expect to learn how the COPA platform could benefit patients, caregivers, and healthcare teams, as well as facilitate strategic partnerships, licensing agreements, and future growth opportunities for Berkshire Biomedical.
This final webinar presents a unique opportunity to engage directly with the company’s leadership before the conclusion of Berkshire Biomedical’s StartEngine campaign. Interested individuals can register for the webinar to gain insights into the groundbreaking innovations shaping the future of medication delivery and management.
About Berkshire Biomedical Corporation
Berkshire Biomedical Corporation is a pioneering medical device company that specializes in utilizing biometric technologies and HIPAA-compliant cloud-based systems to deliver personalized medication to authenticated users securely. The company’s flagship product, the Computerized Oral Prescription Administration System (COPA), is designed to dispense controlled and non-controlled liquid oral medications only to the Authenticated Intended User (AIU) following dual biometric identification.
While COPA is currently under development and has not yet received FDA approval for commercial sale, Berkshire Biomedical aims to leverage its technology initially in the delivery of methadone for the treatment of Opioid Use Disorder. Additionally, the company plans to explore opportunities to expand COPA’s applications to other drug therapeutics and clinical settings in collaboration with data analytics companies.
With the support of a $2.0 million Fast-Track Small Business Innovation Research grant from the National Institute on Drug Abuse, Berkshire Biomedical is committed to innovating in the field of medication delivery and management to improve patient outcomes and reduce risks.
For more information about Berkshire Biomedical Corporation and its groundbreaking COPA technology, visit the company’s website and stay updated on the latest developments in Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs, and Gaming.